Jiya Acquisition ^{Priced, Nasdaq: JYAC}

We are a newly-organized blank check company. While we may pursue an initial business combination opportunity in any industry or geographical location, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the biopharmaceutical sector. Our acquisition strategy includes identifying and acquiring an innovative biopharmaceutical company, in-licensing promising assets from pharmaceutical and biotechnology companies, or combining target companies with additional assets to create critical mass in a therapeutic area. We believe our management team working alongside Samsara is uniquely positioned to identify potential acquisition targets, and our collective reach and reputation in the industry will make us a preferred partner. Our dedicated management team puts us in a unique position, if needed, to take operating or board roles and help position the merged company for success following the business combination. We believe that our focus on patient impact and long-term value creation is a meaningful differentiator in the industry. Our selection process will leverage the relationships of our Management and Board and rely on our industry leading approach to diligence and building companies that create significant shareholder value.